Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Department of Gastroenterology, Leiden University Medical Centre, Leiden, The Netherlands.
Journal of Medical Genetics (Impact Factor: 5.64). 07/2007; 44(6):353-62. DOI: 10.1136/jmg.2007.048991
Source: PubMed

ABSTRACT Lynch syndrome (hereditary non-polyposis colorectal cancer) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. The discovery of these genes, 15 years ago, has led to the identification of large numbers of affected families. In April 2006, a workshop was organised by a group of European experts in hereditary gastrointestinal cancer (the Mallorca-group), aiming to establish guidelines for the clinical management of Lynch syndrome. 21 experts from nine European countries participated in this workshop. Prior to the meeting, various participants prepared the key management issues of debate according to the latest publications. A systematic literature search using Pubmed and the Cochrane Database of Systematic Reviews reference lists of retrieved articles and manual searches of relevant articles was performed. During the workshop, all recommendations were discussed in detail. Because most of the studies that form the basis for the recommendations were descriptive and/or retrospective in nature, many of them were based on expert opinion. The guidelines described in this manuscript may be helpful for the appropriate management of families with Lynch syndrome. Prospective controlled studies should be undertaken to improve further the care of these families.

Download full-text


Available from: Gabriel Capellá, Jun 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lynch syndrome is characterised by a familial predisposition of colorectal and endometrial carcinomas in association with a variety of other cancers. The underlying autosomal dominant inheritance has a penetrance of 85-90%. The molecular genetic underlying mechanism is a mutation in one of the mismatch-repair genes. The identification of the molecular genetic basis of Lynch syndrome enabled the implementation of predictive testing in families with a proven mutation. A prerequisite to detect patients with Lynch syndrome is a knowledge of the clinical and histopathological features of this disease. Typical for Lynch syndrome associated carcinomas is the early age of onset of about 45 years as well as the characteristic localisation within the right hemicolon. However, in order to increase the rate of identification of this underestimated syndrome, the awareness of the clinician must extend beyond this classical phenotype. For this purpose close interdisciplinary cooperation is warranted! The cancers are mostly low-differentiated with solid areas without a tubular structure. Crohn's-like lesions as well as peritumoural and tumour-infiltrating lymphocytes may frequently be found in the periphery of the malignant formation. Within the framework of the clinical evaluation of any index patient, an extended family history must be ascertained and matched with the Amsterdam-I and -II criteria as well as with the revised Bethesda criteria. If a patient fulfills these criteria, testing for microsatellite instability and if positive after genetic counselling mutation analysis should be recommended. Patients with a proven mutation and high risk individuals from families with an unidentified underlying mutation are encouraged to participate in an intensified screening programme. Due to the incomplete penetrance there is no recommendation towards prophylactic surgery in high-risk individuals without tumour manifestation. Nevertheless, the effect on quality of life of prophylactic, extended surgery in addition to the obligatory oncologic resection with or without prophylactic hysterectomy needs to be established in prospective controlled trials.
    Zeitschrift für Gastroenterologie 02/2012; 50(2):217-25. DOI:10.1055/s-0031-1281933 · 1.67 Impact Factor
  • Viszeralmedizin / Visceral Medicine 01/2011; 27(4). DOI:10.1159/000331246 · 0.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ZusammenfassungDas Lynch-Syndrom ist ein autosomal-dominant erbliches Tumorsyndrom, bei dem die Betroffenen ein deutlich erhöhtes Risiko für die Entwicklung von Tumoren (insbesondere Kolon- und Endometriumkarzinome, aber auch andere Entitäten) haben. Etwa eine von 550 Personen ist Anlageträger für dieses Syndrom. In Deutschland beschäftigt sich das Deutsche HNPCC-Konsortium im Rahmen des Verbundprojekts «Familiärer Darmkrebs» seit mehr als 10 Jahren mit der Erforschung dieses Tumorsyndroms. Im Zuge dieses Projekts wurde die Lynch-Syndrom-Diagnostik in Deutschland etabliert und weiterhin aktuellen Gegebenheiten angepasst. Außerdem wurde im Rahmen des Verbundprojekts ein engmaschiges Früherkennungsprogramm für Patienten mit einem Lynch-Syndrom sowie für ihre Angehörigen entwickelt. Anders als in anderen Ländern wurde hier von Beginn an ein jährliches Koloskopieintervall gewählt, das sich inzwischen bewährt hat. Die Früherkennungsempfehlungen werden laufend auf ihre Effektivität untersucht und gegebenenfalls auf der Grundlage aktueller Daten angepasst. So wurde zuletzt eine jährliche Endometriumbiopsie bei Frauen in das Programm aufgenommen. Durch eine prospektive Erhebung der Daten zu den Befunden der Früherkennungsuntersuchungen und unter Früherkennung aufgetretener Tumoren soll zukünftig eine individuelle risikoadaptierte Vorsorge ermöglicht werden.
    Viszeralmedizin / Visceral Medicine 01/2011; 27:275-280. DOI:10.1159/000330596 · 0.10 Impact Factor